HTP Antibody production service is designed for high-efficiency parallel evaluation of antibody candidates within a standardized CHO transient workflow.
Reliable HTP Antibody Production Service: Accelerating Early-Stage Decisions
evitria’s High-Throughput (HTP) service supports discovery and early development programs requiring the parallel expression of multiple antibody candidates. Built on our proprietary CHO transient platform, the workflow enables reproducible construct comparison, efficient screening, and robust early decision-making.
Leveraging 15 years of expertise and a track record of 140,000+ transfections, our HTP platform delivers the high-purity material required for deep characterization.
Industry analyses show that more than 30% of clinical-stage antibodies never reach approval1 due to biophysical liabilities. This makes manufacturing-relevant data essential at the earliest stages to identify risks and prioritize your most promising leads.
evitria’s High-Throughput service serves as the strategic entry point into a seamlessly scalable expression journey.
Because every stage from initial screening to gram-scale production is executed within the same proprietary CHO environment, your candidates transition without host-system changes, re-optimization, or comparability concerns.
The workflow supports:
Parallel expression of antibody candidates for early screening
Construct comparison and lead ranking
Selection of promising molecules
Progression toward higher expression scales
Material supply enabling downstream characterization and translational studies
We reject “menu-driven” constraints. Instead, our scientists serve as your Scientific Co-Pilot, collaborating directly with your team to tailor expression, purification, and analytics to your specific molecule format and decision stage.
Optimized for multi-construct screening campaigns, ranging from 24 to several hundred constructs per project, our High-Throughput service workflow ensures you can transition your leads with confidence. To support your decision-making, we specifically prioritize:
”Quality and reproducibility considerations are often delayed until later in vitro and early in vivo experiments. However, this may lead to irreproducible results, and miss out on identifying the best lead candidates.”
Data integrity is the foundation of lead ranking. Every High-Throughput project includes a standardized, high-fidelity analytical package designed to ensure dataset comparability across your entire construct panel:
Titer Measurement: Quantification of expression levels.
HPLC-SEC Analysis: Determination of purity and aggregation states to identify biophysical liabilities early.
CE-SDS Analysis: High-resolution assessment of purity and structural integrity under non-reducing conditions.
Endotoxin Measurement: Ensuring material is suitable for downstream functional assays and early translational studies.
You have questions on our HTP Antibody Production Service and costs?
We’ve got you covered! Regardless of where your research is taking you, Jürgen Lübbehusen is dedicated to supporting you on our HTP antibody production service.
The production of high quality, reproducible material is critical for the development of antibody-based therapeutics. From antibody discovery to lead selection and in vivo studies, our dedicated services in antibody generation provide you with recombinant antibodies at any stage, tailored to your specific needs in terms of quality and speed of delivery.
Antibody Design
Basic research
Our more than 15 years of experience in the field of antibody generation for therapeutic applications enables us to assist you with expert knowledge on your custom antibody design.
AI can generate thousands of sequences, but physical validation remains the bottleneck. evitria bridges this “Verification Gap” by providing high-fidelity candidate expression at scale.
By using our standardized CHO transient platform, we ensure that the sequence is the only variable in your dataset. This eliminates host-cell artifacts and provides the consistent, clean data required to refine your predictive models and accelerate your path to the clinic.
From sequence list to decision-ready antibodies in 4 weeks
Project initiation within 24 hours.
High-throughput projects are run in parallel batches. Once sequences are approved, we initiate your project within 24 hours and execute a standardized CHO transient workflow—expression, purification, QC and analytics – so you receive purified, assay-ready antibodies in a targeted 4 week timeline.
Week 1
Week 2
Week 3
Week 4
Construct cloning
High-throughput Expression (CHO)
High-throughput Purification (Protein A)
Quality Control
Shipment
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Business days
Flexible Project Design & Swiss-Quality Execution
We move beyond “standard packages” to deliver bespoke expression strategies designed specifically for your molecule’s unique characteristics and your project’s critical milestones. We align our workflows to your specific decision-making needs, scaling our services based on:
Turnaround Priorities
Number of Constructs
Molecule Format and Complexity
Analytical Depth
Scale & Yield
From early-stage screening to high-yield expression, evitria is your anchor for reliable data. By combining Swiss-quality precision with 15+ years of exclusive CHO transient expertise, we ensure your most promising candidates progress toward downstream studies with absolute confidence.
Long-lasting, healthy customer relationships are very
important to us. Anonymity is therefore part of our corporate DNA.
“We have been working with evitria for several years and highly appreciate the high consistency of the delivered material.”
Sr. Scientist, Biotherapeutics, Switzerland
“We have been working with evitria since 2022. We appreciate the openness and flexibility of the team, the high speed and quality of the proteins they deliver.”
Radiopharm Theranostics Ltd.
“We are happy paying for the assured quality that evitria brings.”
Sr Scientist, Biotherapeutics, Series B Startup, Boston
Our Solutions
Antibody Production Tailored to Your Specific Field
In our High-Throughput Antibody Production knowledge category, we share practical insights on CHO-based HTP workflows, from expression and purification to QC, developability, automation, and AI-driven discovery. Explore the latest articles and best practices.
evitria’s HTP Antibody Production Service delivers purified, analytics-confirmed material within a 4-week cycle from sequence approval. Learn what factors influence turnaround time and how to plan your screening campaign effectively.
Identifying a high-affinity binder is only the first hurdle in antibody discovery. Developability-by-Design integrates five key biophysical readouts into the selection process to ensure only manufacturable candidates advance.
Top-tier HTP screening leads frequently fail to translate to manufacturing due to host system incompatibilities and production artefacts. This article examines the root causes and how to close the translation gap.
High-Throughput Screening bridges antibody production and data generation, transforming large panels of expressed proteins into actionable biological insights. Understanding this workflow is essential for designing a productive discovery campaign.
High-Throughput Antibody Expression accelerates early-stage discovery by translating digital sequence libraries into physical proteins at unprecedented speed. Discover how HTP production compresses the path from sequence to validated lead.
High-throughput antibody expression exposes technical liabilities that remain invisible until they cause failure at scale. This article identifies the five most common problems and how to proactively avoid them.
Reliable lead comparability in an HTP screening campaign depends on high-fidelity production and a consistent host system. This guide outlines how to structure your campaign to generate decision-grade data.
The host system used during primary screening determines whether lead candidates are genuinely ready for development. CHO-based material ensures data generated at the screening stage translates directly to manufacturing.
Choosing HEK293 cells based on lower upfront cost introduces hidden downstream risks that can cost millions in failed preclinical development. Understanding the true economics of host system selection is critical.
Batch effects are systematic, non-biological sources of variation that distort HTP screening results. Identifying their root causes and applying targeted reduction strategies is essential for reliable lead selection.
Learn when to switch from transient to stable expression in HTP antibody programs. Three technical triggers and a CHO-based strategy that de-risks the move.
At evitria, we provide a specialized HTP service built on four core pillars that ensure your lead candidates transition smoothly from discovery to production:
CHO-Native from the Start: Unlike other providers, we utilize a CHO-native platform throughout. This allows you to avoid host-system transitions (such as moving from HEK293 to CHO) between initial screening and eventual scale-up.
Comparability-Focused Workflows: Our standardized processes are engineered to reduce variability across construct panels, providing the reliable data needed for confident selection.
Seamless Scalability: We enable you to progress candidates toward larger-scale expression within the same consistent platform, eliminating the need to re-validate in a new system.
Scientific Flexibility: We do not believe in a “one-size-fits-all” approach. Every project design is aligned to your specific molecule characteristics and your current decision stage.
Choosing CHO cells from day one is a strategic de-risking move. While HEK293 cells are often used for speed, they can produce results that differ from the industry-standard CHO cells used in manufacturing. By starting in CHO, you ensure that biophysical properties – such as stability and glycosylation – remain consistent from discovery to clinic, effectively closing the translational gap.
We understand that every day counts in competitive antibody drug discovery and have built our Zurich facility for maximum responsiveness through a fully integrated and robotics-assisted workflow.
Once your sequences are approved, our automated systems prepare expression vectors and trigger the transfection process immediately. This 24-hour initiation combined with our exclusive focus on transient CHO expression allows us to deliver high-purity recombinant proteins in as little as 4 weeks.
Costs are primarily driven by the number of constructs, molecule format complexity (e.g., bispecifics), and required yield. Because we offer bespoke proposals rather than “fixed menus,” we encourage you to share your project parameters so our team can provide a quote tailored to your specific analytical needs and decision stage.
Every HTP project includes a comprehensive analytical QC package to ensure data integrity:
Titer measurement
HPLC-SEC analysis
Endotoxin measurement
CE-SDS analysis (Non-Reducing)
Efficiency is core to our platform. Every project is initiated within 24 hours of sequence approval. For our HTP workflow, we follow our standard transient CHO production timeline of approximately 4 weeks, ensuring you receive screening-ready material without compromising on Swiss-quality precision.
This website uses cookies to enhance your browsing experience and provide personalized services. We require your consent to set these cookies on your device. Please note that we also use cookies from US companies that have not signed up to the EU-US data protection agreement.
Your Privacy
This site uses tracking technologies. You may opt in or opt out of the use of these technologies.
Marketing cookies and services are used to deliver personalized advertisements, promotions, and offers. These technologies enable targeted advertising and marketing campaigns by collecting information about users' interests, preferences, and online activities.
Analytics cookies and services are used for collecting statistical information about how visitors interact with website. These technologies provide insights into website usage, visitor behavior, and site performance to understand and improve the site and enhance user experience.
Personalization cookies enable the website to remember your choices and provide enhanced, more personal features. These cookies may track your preferences and show you relevant content based on your browsing patterns.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedback, and other third-party features.
Essential cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website.
